RXRX Today - Aug 06: Cash Burn Concerns
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
RXRX Today - Aug 06: Cash Burn Concerns
-
Letto da:
-
Di:
So, here’s the scoop. RXRX got smoked today. It seems like cash burn is the big worry for folks right now. Investors are feeling the heat after the company reported a Q2 loss and missed revenue estimates. Not a great look, right? People were already on edge after the results update from August 5, and it seems like this just added fuel to the fire.
Now, let’s chat about why this happened. The articles are saying Recursion's been struggling with returns and is trading above what some think is fair value. Basically, it’s like when you’re trying to sell a used game for way too much, and no one’s biting. Plus, the whole AI drug development angle hasn’t been enough to convince everyone that it’s worth the price tag. Investors are questioning if the hype around AI in drug discovery is really living up to the expectations.
Oh, and here’s something worth knowing: Roche and Recursion are still pushing forward with their AI-targeted brain disease project. So, there’s some action happening in the lab, but it seems like the market’s not super jazzed about the immediate financials.
To wrap it up, RXRX is facing some tough questions from investors, and it’s clear that cash burn is a hot topic. Remember, I’m just here to share what’s happening, not to give any financial advice. Keep it chill, and see you next time!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione